We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
+ 34-608-087-655
nsaglio@yahoo.co.uk
Title Image

Blog

Home  /  Clinical Trials   /  Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced that the first patient was dosed in a Phase 1/2 study of DF1001 at The University of Texas MD Anderson Cancer Center in Houston. Dragonfly’s DF 1001 clinical trial is currently recruiting patients with various types of advanced solid tumors that express human epidermal growth factor receptor 2 (HER2).

“DF1001 is the first candidate from our TriNKET™ Platform to enter the clinic and marks our transition to a clinical-stage company,” said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. “We are pleased to collaborate with the immunotherapy experts at MD Anderson as we explore the differentiated safety profile that our NK-cell engagers may offer over existing immuno-oncology options. We look forward to advancing other assets in our portfolio with the same purpose and focus that allowed us to advance DF1001 to patients.”

Read More